“The Arrowhead Pharmaceuticals Inc. interim study results from the open label phase 2 clinical ARO-AAT, a RNAi therapy, provide proof of the principle that silencing alpha-1-antitrypsin Z protein production in affected individuals has significant and meaningful...
We are excited to announce that Senators Amy Klobuchar (D-MN) and Roger Wicker (R-MS) introduced the Plasma Donation Awareness Act (S. 1281) in the Senate yesterday. S. 1281 is a bill to update the blood donation public awareness campaign of the Department of Health...
The US COPD Coalition (USCC) has announced their next webinar, which will feature Allison Cihla, MD, Medical Director of Intensive Care and Cardiopulmonary Services at Preston Memorial Hospital in Kingwood, West Virginia. Dr. Cihla will answer many frequently asked...
Over 16 million people in the US have COPD1 and up to 60% of COPD cases go undiagnosed. According to the World Health Organization, COPD is the third leading cause of death globally. COPD continues to be a leading cause of disabling symptoms and suffering. Pulmonary...
The Alpha-1 Foundation has received the following correspondence from Grifols on March 26, 2021: March 26, 2021 RE: Voluntary Withdrawal of Gamunex-C Lot No. A3GLE01462 As part of our ongoing commitment to patient safety and product quality, Grifols recently...
